AxoGen
在场
是其中之一......
AxoGen 是一家在股票代码 AXGN (US) 下上市的公司。
AxoGen 在 2 个国家有直接业务。
他们在：
高管
查看带有其 34 名主要高管的组织结构图
AxoGen 搜索最多的简介
- Karen Zaderej, President, Chief Executive Officer and Chairman of ...
- Michael Dale, Chief Executive Officer
- John Johnson, Director
高管在AxoGen变化
- Karen Zaderej, President, Chief Executive Officer and Chairman of the Board , 将于 20255月7 退休 (新闻发布的2024八月8号).
- Paul Thomas 曾任 Director, 现任 Chairman of the Board (新闻发布的2024八月8号).
- Michael Dale已作为Chief Executive Officer加入公司 (新闻发布的2024八月8号).
创建提醒
跟踪 AxoGen 的高管变动
健康
AxoGen 拥有 1,982 家竞争者，其中包括 UnitedHealth Group (美国(美洲))、UnitedHealthcare (美国(美洲)) 和 Siemens Healthineers (德国)。
Popular M&A news in 健康
- Oura Health 刚刚宣布为 200 筹款数百万美元。 (公布2024十二月20号).
- Neuronetics 已收购 Greenbrook TMS (公布2024十二月10号).
- Cleerly 刚刚宣布为 106 筹款数百万美元。 (公布2024十二月9号).
健康 行业的其他推荐联系人
消息
AxoGen 的最新新闻稿
- Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update
- Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024
- Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®
- Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4)
- Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia
- Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference
- Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®
- Axogen, Inc Reports First Quarter 2024 Financial Results
- Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™
- Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
- View more press releases Close
通过电子邮件
